Cohere Health to Further Reduce Administrative Burden for Providers via Epic’s Payer Platform by Seini Moimoi | Apr 3, 2024 | Portfolio News
Mirum Pharmaceuticals’ LIVMARLI (maralixibat oral solution) Receives Positive Reimbursement Recommendation by Canada’s CADTH for Patients with Cholestatic Pruritus in Alagille Syndrome by Seini Moimoi | Apr 2, 2024 | Portfolio News
Mirum Pharmaceuticals’ LIVMARLI Receives FDA Approval for Treatment of Cholestatic Pruritus in Patients with Progressive Familial Intrahepatic Cholestasis by Seini Moimoi | Mar 13, 2024 | Portfolio News
Lexeo Therapeutics Announces Closing of Oversubscribed $95.0 Million Equity Financing by Seini Moimoi | Mar 13, 2024 | Portfolio News
CuraSen Therapeutics Announces Oral Presentation of Additional Positive Phase 2a Data with CST-2032/CST-107 in Patients with Alzheimer’s or Parkinson’s Disease at AD/PD™ 2024 International Conference by Seini Moimoi | Mar 7, 2024 | Portfolio News
CG Oncology Announces First Patient Dosed in PIVOT-006 Phase 3 Clinical Trial of Cretostimogene in Intermediate-risk Non-Muscle Invasive Bladder Cancer by Seini Moimoi | Feb 27, 2024 | Portfolio News
BioAge Announces $170 Million Oversubscribed Series D Financing to Accelerate Development of Obesity and Metabolic Disease Therapeutics by Seini Moimoi | Feb 13, 2024 | Portfolio News
Endogenex™ Receives IDE Approval to Initiate Pivotal Clinical Study by Seini Moimoi | Jan 30, 2024 | Portfolio News
Vera Therapeutics Presents Positive 72-Week Data Showing eGFR Stabilization in the Phase 2b ORIGIN Clinical Trial OLE in IgA Nephropathy by Seini Moimoi | Jan 25, 2024 | Portfolio News
Endeavor BioMedicines Successfully Completes Phase 2a Trial Of ENV-101 In Patients With Idiopathic Pulmonary Fibrosis by Seini Moimoi | Jan 24, 2024 | Portfolio News
